S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Fennec Pharmaceuticals (NASDAQ:FENC) Posts Quarterly Earnings Results, Hits Estimates

Saturday, May 14, 2022 | MarketBeat

Fennec Pharmaceuticals (NASDAQ:FENC - Get Rating) posted its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14), MarketWatch Earnings reports.

Shares of NASDAQ FENC traded up $0.20 during mid-day trading on Friday, hitting $5.50. The company had a trading volume of 218 shares, compared to its average volume of 32,312. The company has a debt-to-equity ratio of 0.32, a current ratio of 13.53 and a quick ratio of 13.54. The business's 50-day simple moving average is $5.80 and its 200-day simple moving average is $5.80. Fennec Pharmaceuticals has a 12 month low of $2.96 and a 12 month high of $6.55. The firm has a market cap of $143.22 million, a P/E ratio of -7.91 and a beta of -0.07.

Several research firms have recently commented on FENC. Wedbush reaffirmed an "outperform" rating on shares of Fennec Pharmaceuticals in a report on Wednesday, April 27th. Zacks Investment Research downgraded Fennec Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $11.13.


A number of large investors have recently bought and sold shares of FENC. Bank of America Corp DE increased its holdings in shares of Fennec Pharmaceuticals by 134.8% in the fourth quarter. Bank of America Corp DE now owns 11,383 shares of the company's stock valued at $51,000 after purchasing an additional 6,536 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Fennec Pharmaceuticals by 189.1% during the fourth quarter. Citadel Advisors LLC now owns 14,874 shares of the company's stock worth $65,000 after acquiring an additional 31,574 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Fennec Pharmaceuticals by 23,280.0% during the first quarter. JPMorgan Chase & Co. now owns 16,366 shares of the company's stock worth $91,000 after acquiring an additional 16,296 shares during the period. Geode Capital Management LLC raised its holdings in shares of Fennec Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 19,909 shares of the company's stock worth $187,000 after acquiring an additional 1,983 shares during the period. Finally, Morgan Stanley increased its stake in shares of Fennec Pharmaceuticals by 6.0% during the 2nd quarter. Morgan Stanley now owns 43,430 shares of the company's stock worth $316,000 after purchasing an additional 2,453 shares during the last quarter. 43.62% of the stock is owned by hedge funds and other institutional investors.

About Fennec Pharmaceuticals (Get Rating)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Read More

Earnings History for Fennec Pharmaceuticals (NASDAQ:FENC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Fennec Pharmaceuticals right now?

Before you consider Fennec Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.

While Fennec Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.